Key result
Robust clinical trials for emerging immunotherapies in pediatric multiple sclerosis are necessary to optimize therapy and monitor toxicities, despite challenges like small patient populations.
Highlights the critical need for dedicated pediatric clinical trials in multiple sclerosis to ensure safe and effective use of emerging immunotherapies.
Immunotherapy selection in pediatric MS should remain individualized pending better data; leaves open standardized protocols for this rare population.
To date, none of the formative clinical drug trials in multiple sclerosis (MS) have included children. Just as in other fields in pediatrics, current prescribed therapies are off-label and are based on the results of adult studies. Emerging oral, injectable and intravenous immunotherapies appear to be more efficacious, but simultaneously have more worrisome side effects. In order to optimize therapy for children with MS, these therapies must be evaluated in robust clinical trials with a focus on monitoring for potential toxicities both in the short and long term. Many challenges exist in conducting clinical trials in children, including smaller patient populations. International collaboration and mandated pediatric investigation plans will facilitate the process of conducting these valuable clinical trials, which may lend to a better understanding of MS overall.
No takes yet. Share an insight, caveat, or question.
Venkateswaran et al. (2012) conducted a review in pediatric multiple sclerosis. immunotherapies was evaluated. Robust clinical trials for emerging immunotherapies in pediatric multiple sclerosis are necessary to optimize therapy and monitor toxicities, despite challenges like small patient populations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: